US Cases / Year
~83,000
Sixth most common cancer in the United States. Approximately 83,190 new cases and 16,840 deaths estimated for 2024.[1]
What Is It
Definition, mechanism, and the clinical reality of bladder cancer at end of life. What the hospice team needs to understand on day one.
Muscle-Invasive at Presentation
~25%
About 25% of newly diagnosed bladder cancers are muscle-invasive (≥T2) at presentation — this distinction defines the entire surgical, systemic, and palliative trajectory.[2]
Metastatic 5-Year Survival
~8%
Distant-stage bladder cancer carries a 5-year relative survival of approximately 8%. Pre-immunotherapy era survival was even lower.[1]
Male-to-Female Ratio
3–4 : 1
Bladder cancer is male-predominant. Men have 3–4× higher incidence than women, though women often present at more advanced stages with worse outcomes.[3]
Bladder cancer is a malignancy of the urothelium — the transitional cell epithelium lining the bladder, ureters, and renal pelvis. The vast majority (approximately 90%) are urothelial (transitional cell) carcinomas. The disease exists on a spectrum from superficial, papillary tumors that recur but rarely kill, to deeply invasive and metastatic disease that is among the most lethal of solid tumors. The clinical reality for hospice is almost always the latter — patients who have exhausted surgical and systemic options, or whose performance status no longer permits treatment.[2]
What makes bladder cancer unique at end of life is the convergence of three simultaneous threats: hematuria that can range from chronic nuisance to life-threatening hemorrhage requiring emergent intervention; urinary obstruction from tumor encasement of the ureters or bladder outlet, causing hydronephrosis and progressive renal failure; and pelvic pain from local tumor invasion into the pelvic sidewall, sacral nerve roots, and surrounding organs. These three problems do not occur in isolation — they interact, and they all attack the most private and dignity-sensitive functions of the human body.[4]
The median age at diagnosis is 73. Most hospice patients with bladder cancer are elderly men with significant comorbidities — cardiovascular disease, chronic kidney disease, COPD from the same tobacco exposure that caused the cancer. Many have undergone radical cystectomy with urinary diversion, meaning their urinary anatomy has been permanently altered. Before you can manage any symptom in this disease, you must know exactly what urinary anatomy this patient has.[5]
🧭 Clinical framing
Bladder cancer at end of life is defined by three converging threats — hematuria that can be catastrophic, urinary obstruction that causes renal failure, and pelvic pain from local tumor invasion or post-surgical anatomy. Before you can manage any of these, you need to know exactly what urinary anatomy this patient has. Has there been a cystectomy? What type of urinary diversion — ileal conduit (urostomy), neobladder, continent cutaneous pouch? Are ureteral stents in place? Bilateral nephrostomy tubes? Each of these creates an entirely different clinical landscape. Know the surgery before the visit. Write it on the front of the chart. It changes everything.
"Three things define bladder cancer at the end: blood, blockage, and pain — and all three of them happen in the most private part of a person's body. Before you walk in the door, know the plumbing. Ileal conduit? Neobladder? Stents? If you don't know the anatomy, you can't manage the symptoms, and you definitely can't have the right conversation about what's coming."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, histologic subtypes, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- Cystoscopy with biopsy: Gold standard — direct visualization and tissue sampling of bladder lesions. Definitive diagnosis requires histopathologic confirmation.[6]
- CT urogram: Standard imaging for staging and upper urinary tract assessment. Evaluates for hydronephrosis, lymphadenopathy, and distant metastases.[7]
- Urine cytology: High sensitivity for high-grade urothelial carcinoma (70–90%). Low sensitivity for low-grade tumors. Useful for surveillance and initial workup.[6]
- CT/MRI chest-abdomen-pelvis: Complete metastatic staging. Bone scan if symptomatic or elevated alkaline phosphatase.
- TURBT (transurethral resection of bladder tumor): Both diagnostic and therapeutic for non-muscle-invasive disease. Pathology determines depth of invasion — the single most important prognostic factor.[8]
Histology & Staging
- Urothelial (transitional cell) carcinoma: ~90% of all bladder cancers. Further classified as papillary vs. flat (CIS), low-grade vs. high-grade.[2]
- Squamous cell carcinoma: ~3–5% in Western countries. Associated with chronic irritation — schistosomiasis, long-term indwelling catheter, chronic UTI.[9]
- Adenocarcinoma: Rare (~1–2%). Associated with urachal remnants or chronic bladder exstrophy.
- NMIBC staging: Ta (papillary, confined to mucosa), T1 (invading lamina propria), CIS (carcinoma in situ — flat, high-grade, aggressive).[8]
- MIBC staging: T2 (muscularis propria invasion), T3 (perivesical fat), T4 (adjacent organs — prostate, uterus, pelvic wall).[2]
- Metastatic: N+ (regional lymph nodes) or M1 (distant metastases — bone, lung, liver most common).
What to Look for in Hospice Records
- Urinary diversion type and date — this is the single most important piece of surgical history in bladder cancer. Ileal conduit (urostomy — most common diversion; external stoma bag); neobladder (continent reconstruction using ileal segment — patient voids per urethra, may self-catheterize); Indiana pouch or continent cutaneous diversion (catheterizable pouch — intermittent catheterization through abdominal stoma).[10]
- Prior TURBT history and recurrence pattern: Number of resections, interval between recurrences, prior intravesical therapy response — establishes disease biology and treatment exhaustion.
- Ureteral stent status: Bilateral ureteral obstruction is common in advanced disease. Are stents in place? When were they placed? When do they need exchange? Who manages them (urology vs. interventional radiology)?[11]
- Renal function trend: Obstruction causes hydronephrosis and progressive renal failure. Track creatinine trajectory — a rising creatinine in the setting of known ureteral involvement indicates progression toward uremia.[11]
- Pelvic radiation history: Irradiated tissue has a fundamentally different bleeding risk profile, healing capacity, and fistula risk. Prior radiation changes every management decision.
- Prior BCG therapy: Intravesical BCG immunotherapy for NMIBC. Know if patient received it, how many courses, and whether disease was BCG-responsive or BCG-unresponsive — this defines prior treatment trajectory.[12]
💡 For families
Your loved one's diagnosis has already been confirmed — the diagnostic tests were completed before hospice enrollment. The focus now is entirely on comfort and quality of life, not further testing. If your care team asks about prior surgeries or procedures, they need this information to provide the best possible symptom management.
Causes & Risk Factors
Modifiable and non-modifiable risk factors. Relevant for family conversations, understanding disease etiology, and answering "why did this happen?"
Modifiable Risk Factors
- Tobacco smoking: The most important modifiable risk factor. Accounts for approximately 50% of bladder cancer in men and 30% in women. Smokers have a 3–7× increased risk compared to never-smokers. Risk persists for decades after cessation — quitting reduces but never fully eliminates the risk.[13]
- Occupational chemical exposure: Aromatic amines (benzidine, beta-naphthylamine, 4-aminobiphenyl). High-risk industries: rubber manufacturing, dye production, textile, printing, leather tanning, trucking (diesel exhaust). Latency period 20–40 years. Always ask about lifetime occupational history.[14]
- Chronic bladder irritation: Recurrent UTI, long-term indwelling catheter (≥10 years), bladder stones — associated specifically with squamous cell carcinoma variant.[9]
- Schistosomiasis: Schistosoma haematobium — endemic in sub-Saharan Africa and Middle East. Most common cause of squamous cell bladder cancer globally.[9]
Non-Modifiable & Iatrogenic
- Prior pelvic radiation: For prostate, cervical, or rectal cancer. Latency period 10–20 years. 1.5–4× increased risk of secondary bladder cancer.[15]
- Cyclophosphamide chemotherapy: Known urothelial carcinogen. Latency 6–13 years. Risk is dose-dependent. Prior cancer survivors on alkylating agents are at increased risk.[15]
- Aristolochic acid exposure: Found in some traditional herbal medicines (Aristolochia species). Causes Balkan endemic nephropathy and upper tract urothelial carcinoma.
- Pioglitazone: Diabetes medication — some studies suggest increased bladder cancer risk with prolonged use (>2 years). Evidence remains debated but relevant to history-taking.
- Age, sex, race: Median age at diagnosis is 73. Male predominance 3–4:1. Bladder cancer disproportionately affects older men with multiple comorbidities.[1]
❤️ For families: "Why did this happen?"
Families often ask this question. Bladder cancer has strong associations with tobacco and occupational exposures, but many patients develop it without identifiable risk factors. If your loved one smoked, understand that nicotine addiction is a disease — not a moral failure. They did not choose cancer. If the cancer was related to workplace chemical exposure, the anger you may feel toward the employer or the system is legitimate and understandable. Neither scenario is something your loved one deserves blame for.
⚕ Health disparities
Black Americans and Hispanic Americans with bladder cancer present at more advanced stages and have worse survival outcomes compared to white Americans — even when adjusting for stage at diagnosis. These disparities reflect systemic differences in access to early cystoscopy and diagnostic workup, occupational exposure surveillance, treatment intensity at academic cancer centers, and clinical trial enrollment. Awareness of these patterns should heighten clinical vigilance and attention to equitable symptom management in hospice.[16]
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
Bladder cancer treatment spans a wide spectrum — from endoscopic resection for superficial tumors to radical cystectomy with urinary diversion for muscle-invasive disease to multi-agent chemotherapy and immunotherapy for metastatic disease. The treatments a patient has already received define the complications, anatomy, and symptom profile the hospice team will manage.[2]
Non-Muscle-Invasive (NMIBC)
- TURBT: Transurethral resection of bladder tumor — primary treatment and surveillance tool. Patients may have had many TURBTs over years of recurrent disease.[8]
- Intravesical BCG: Bacillus Calmette-Guérin immunotherapy — standard adjuvant for high-risk NMIBC. Causes chronic cystitis-like symptoms (frequency, urgency, dysuria, hematuria). Know if patient received BCG and their response pattern.[12]
- Intravesical chemotherapy: Mitomycin C, gemcitabine — perioperative or adjuvant. Lower toxicity than BCG but less effective for high-risk disease.
Muscle-Invasive (MIBC)
- Radical cystectomy with urinary diversion: Gold standard for muscle-invasive disease. Removes bladder, prostate and seminal vesicles in men; or uterus, ovaries, fallopian tubes, and anterior vaginal wall in women (anterior pelvic exenteration). Urinary diversion is mandatory — ileal conduit, neobladder, or continent cutaneous diversion.[10]
- Neoadjuvant cisplatin-based chemotherapy: Gemcitabine + cisplatin (GC) — standard before cystectomy in cisplatin-eligible patients. 5–8% absolute survival benefit at 5 years.[17]
- Trimodality bladder preservation: Maximal TURBT + concurrent chemoradiation (cisplatin or 5-FU/mitomycin). Selected patients who refuse or are ineligible for cystectomy. Bladder preserved in ~75% of responders.[18]
Metastatic / Systemic Therapy
- Gemcitabine + cisplatin (GC): First-line standard for cisplatin-eligible patients. Median OS 12–15 months. Requires GFR >60 mL/min, ECOG 0–1.[19]
- Gemcitabine + carboplatin: Cisplatin-ineligible patients. Inferior to GC but standard alternative. Median OS ~9 months.[20]
- Pembrolizumab: Anti-PD-1 checkpoint inhibitor. FDA-approved second-line post-platinum (KEYNOTE-045: median OS 10.3 months vs 7.4 chemo). Also first-line in cisplatin-ineligible PD-L1+ patients.[21]
- Enfortumab vedotin + pembrolizumab: EV-302 trial — new first-line standard regardless of cisplatin eligibility. Median OS 31.5 months vs 16.1 months with platinum-based chemo. Paradigm-shifting data.[22]
- Erdafitinib: FGFR inhibitor for FGFR2/3-altered tumors. Oral targeted therapy. Response rates ~40% in selected population.[23]
Palliative Procedures
- Ureteral stenting: Bilateral obstruction — percutaneous nephrostomy or retrograde ureteral stents. Restores renal function. Know if stents are in place and exchange schedule.[11]
- Bladder irrigation and clot evacuation: For hematuria with clot retention. Three-way Foley catheter with continuous NS irrigation. May require cystoscopic clot evacuation.[24]
- Hemostatic radiation: Palliative radiation for refractory hematuria — single fraction or hypofractionated course (e.g., 21 Gy in 3 fractions). Response rates 50–80%. Highly effective and underused.[25]
- Transurethral fulguration: Endoscopic cauterization of bleeding tumor. Requires anesthesia and cystoscopy suite.
- IPC for malignant ascites: If peritoneal carcinomatosis develops. Indwelling peritoneal catheter for repeated drainage.
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
Bladder cancer is increasingly responsive to immunotherapy and targeted agents. The treatment landscape has shifted dramatically since the approvals of pembrolizumab, enfortumab vedotin, and erdafitinib. Molecular testing results (PD-L1 expression, FGFR2/3 alterations) should be known before closing the door on all systemic options — because meaningful responses can occur even in heavily pretreated patients.[21]
- 01ECOG 0–1 with cisplatin-eligible renal function (GFR >60): Gemcitabine + cisplatin first-line offers a meaningful OS benefit of 12–15 months. Cisplatin eligibility is based on renal function, hearing, neuropathy, and NYHA class — these specific criteria matter and should be documented.[19]
- 02Enfortumab vedotin + pembrolizumab in ECOG 0–1: The EV-302 trial established a new first-line standard regardless of cisplatin eligibility — median OS 31.5 months, nearly doubling the historical benchmark. This is the strongest evidence in metastatic bladder cancer to date. Patients who are functionally adequate should be aware this option exists.[22]
- 03Pembrolizumab second-line post-platinum in ECOG 0–2: KEYNOTE-045 demonstrated meaningful response rates with durable responses in responders. Some patients achieve long-lasting disease control — checkpoint inhibitor responders have a qualitatively different trajectory than non-responders.[21]
- 04Erdafitinib for FGFR2/3-altered tumors post-platinum: Targeted oral therapy in ECOG 0–2. Approximately 15–20% of advanced urothelial carcinomas harbor FGFR alterations. Response rates ~40%. Manageable toxicity. Molecular testing should have been performed prior to hospice enrollment — confirm the result is in the chart.[23]
- 05Hemostatic radiation for hematuria — even in hospice-eligible patients: A short course of palliative radiation (5–10 fractions, sometimes single fraction) that stops catastrophic hematuria is a comfort intervention, not disease treatment. This decision should be made proactively — contact radiation oncology before the hemorrhage crisis, not during it.[25]
- 06Ureteral stenting to restore renal function: If bilateral ureteral obstruction is the primary driver of clinical decline and stenting would restore adequate renal function to permit QoL goals (alert, comfortable, at home), this is a comfort decision worth discussing individually. Not every obstruction should be stented — but not every one should be left untreated either.[11]
- 07Patient goals explicitly include life-prolongation with full prognosis understanding: A well-informed patient who understands that metastatic bladder cancer is incurable but chooses active therapy to extend quality time should receive it without judgment. The conversation is about tradeoffs — not about permission.
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
Bladder cancer patients are frequently referred to hospice late — often after multiple lines of systemic therapy, escalating complications from urinary obstruction, and progressive functional decline. Studies of end-of-life care in urothelial carcinoma consistently show that patients who receive aggressive cancer-directed therapy in the last month of life have worse quality of death without improved survival. Earlier palliative care integration is associated with better symptom control and reduced end-of-life ICU utilization.[26]
- 01ECOG ≥3: No evidence of survival benefit from systemic chemotherapy or immunotherapy at performance status ≥3. Response rates plummet, toxicity dominates, and quality of remaining time is consumed by treatment rather than living. This threshold is well-established across all solid tumors and applies here.[26]
- 02Progression through platinum-based chemotherapy and pembrolizumab: Response rates to further-line therapies drop below 10% in unselected patients. Without a specific actionable target (FGFR alteration, high TMB), the probability of meaningful response is insufficient to justify toxicity burden.[21]
- 03Bilateral ureteral obstruction with declining renal function not amenable to stenting: GFR <20 and declining represents a uremic trajectory. When tumor encasement of the ureters prevents stent placement and percutaneous nephrostomy is either technically impossible or inconsistent with patient goals, prognosis is weeks to months regardless of tumor-directed therapy.[11]
- 04Severe hematuria refractory to all hemostatic interventions including radiation: When continuous bladder irrigation, antifibrinolytics, transurethral fulguration, and hemostatic radiation have all been attempted or are no longer feasible, the disease has moved beyond therapeutic control. Transition to comfort protocol focused on preventing clot-related obstruction and managing pain.[24]
- 05Uncontrolled pelvic pain requiring high-dose opioids with performance status driven too low for systemic therapy: When pelvic pain from local tumor invasion requires dose-limiting opioids that impair function, the clinical trajectory is clear. Multimodal pain management becomes the priority — not further systemic therapy.
- 06Estimated survival <6 months: Hospice enrollment is appropriate, beneficial, and guideline-supported. All thresholds above converge on this timeline.
- 07Patient goals shift to comfort and dignity at home: Bladder cancer patients are making decisions about urinary function, continence, and bodily control at the same time they are making decisions about dying. These are not separate conversations — they are the same conversation. When a patient says "I want to be comfortable and I want to be home," that is clarity, not defeat. Name it as such.
📋 The dignity dimension
Bladder cancer uniquely forces patients to make simultaneous decisions about urinary function and about dying. A patient weighing whether to continue chemotherapy is also weighing whether to accept another month of catheter management, hematuria, and incontinence — or whether dignity and autonomy at home matter more. Clinicians who separate the treatment conversation from the dignity conversation are missing the point. They are the same conversation. Ask directly: "How are you doing with the daily reality of managing your urinary symptoms — and how does that factor into what you want going forward?"
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Hemostatic Radiation for Hematuria
Grade ASingle fraction 8–10 Gy or hypofractionated 21 Gy / 3 fractions
Palliative radiation for bladder cancer hematuria has response rates of 50–80% across multiple series. Single-fraction and hypofractionated regimens are feasible even in declining patients with limited transportation capacity. This is the most important and most underused out-of-the-box approach in bladder cancer. It is a comfort intervention — not cancer treatment. Have the conversation with radiation oncology before the bleeding crisis, not during it.[25]
Continuous Bladder Irrigation Protocol
Grade BNS irrigation at 100–200 mL/hr via three-way Foley catheter
Not a new treatment but an underutilized hospice-compatible intervention for clot retention prevention. Continuous bladder irrigation (CBI) prevents clot formation before it becomes acute obstruction. In patients with chronic gross hematuria and a catheter already in place, CBI can be managed at home with appropriate family education and nursing support. Prevents the emergency of clot retention, which causes severe pain and requires hospital-level intervention.[24]
Acupuncture for Pelvic Pain
Grade BPC6, ST36, local pelvic acupoints; 2× weekly sessions
Evidence supports acupuncture for pelvic cancer pain, including bladder and gynecologic malignancies. Multiple observational studies and small RCTs demonstrate reduced opioid requirements and improved pain scores. Safe in patients without coagulopathy. Contraindicated in patients with active bleeding or on therapeutic anticoagulation. Refer to licensed acupuncturist with oncology experience.[27]
MBSR / Mindfulness for Pelvic Symptoms
Grade B8-week structured program or abbreviated hospice-adapted protocol
Bladder dysfunction generates significant anxiety and hypervigilance — the constant awareness of urgency, incontinence risk, and visible urine output creates a feedback loop of pelvic floor tension. Mindfulness-based stress reduction (MBSR) specifically reduces urgency perception and pelvic floor tension that worsens urinary symptoms. Meta-analyses show improved anxiety and pain scores in cancer populations. Feasible in patients with adequate cognition.[28]
Hypnotherapy for Bladder Urgency and Pain
Grade C4–6 clinical sessions; self-hypnosis training for home use
Some bladder-specific data exists for hypnotherapy in urgency and pain modulation, primarily from functional bladder disorder literature. In the cancer setting, evidence is limited but biological plausibility is strong — central pain modulation and autonomic nervous system effects. Appropriate referral in patients with adequate cognition and motivation. No contraindications specific to bladder cancer.
Pelvic Floor Physical Therapy
Grade CWeekly sessions adapted to functional status; home exercise program
Even in advanced disease, targeted pelvic floor work can reduce urgency, pelvic discomfort, and incontinence episodes. Patients post-cystectomy with neobladder may benefit from pelvic floor strengthening for continence. Patients with intact bladders may benefit from relaxation techniques for urgency. Refer to PT with hospice or palliative care experience. Feasibility depends on functional status.[29]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to bladder cancer. Patients will use supplements — this section helps you have the right conversation.
"Patients are going to use supplements whether we ask or not. The conversation is: 'I want to know what you're taking — not to judge you, but because some of these interact with your pain medications and blood thinners, and in bladder cancer specifically, some supplements that seem harmless can actually make bleeding worse or irritate the bladder.' Say it plainly. Most of the time they're relieved someone asked."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger | Grade B | 1 g/day capsule form or fresh ginger tea 2–3×/day | Nausea from chemotherapy, uremia, and opioid use. Particularly important in bladder cancer where nausea has multiple simultaneous causes. Multiple RCTs support anti-emetic efficacy.[30] | Generally safe. Mild antiplatelet effect at high doses — use caution in active hematuria. Minimal CYP interactions at food-source doses. |
| Green Tea (EGCG) | Grade C | Brewed green tea, 2–4 cups/day (food-source doses only) | Preclinical anti-proliferative signal in urothelial cell lines. Antioxidant properties. Safe and acceptable as brewed tea.[31] | Avoid supplemental EGCG capsules — hepatotoxicity risk at high doses. Caffeine content may exacerbate bladder irritation in some patients. Mild CYP3A4 interaction at high doses. |
| Saw Palmetto | Grade C | 320 mg standardized extract daily | Lower urinary tract symptom relief including urgency and frequency. Limited evidence specific to malignant obstruction but may reduce symptom burden from concurrent BPH or residual bladder irritation. | Generally safe. Mild CYP2C9/CYP3A4 interaction potential. Theoretical antiandrogen effect. Do not use as substitute for medical management of obstruction. |
| Pumpkin Seed Extract | Grade D | 500 mg extract daily or 10 g whole seeds | Traditional use for bladder and urinary symptoms. Some data from overactive bladder studies suggesting reduced nocturia and urgency. Safe with no significant drug interactions. | No significant interactions. Reasonable to support if patient finds comfort in it. Not a substitute for pharmacologic urgency management. |
| Marshmallow Root | Grade C | 1–2 g dried root as tea, 2–3×/day | Demulcent — may soothe urethral and bladder mucosal irritation. Traditional use in UTI and urinary discomfort. Mucilage coats irritated tissue. | Safe at food-source doses. No significant drug interactions. May delay absorption of oral medications if taken simultaneously — separate by 1 hour. |
🚫 Avoid in Bladder Cancer
- Cranberry supplements (high-dose concentrated proanthocyanidin capsules): Concentrated cranberry supplements may increase bladder irritation in patients with active tumor or mucosal inflammation. Also significant warfarin interaction — INR elevation in anticoagulated patients. Food-source cranberry juice in small amounts is different and generally tolerable.[32]
- Diuretic herbs — dandelion, juniper berry, horsetail: Any supplement that increases urine flow is contraindicated in patients with urinary obstruction or clot retention. Increased flow through an obstructed system causes worsening hydronephrosis, pain, and can dislodge clots causing acute retention.
- High-dose fish oil and Ginkgo biloba: Antiplatelet effect compounds hemorrhage risk in patients with hematuria. Absolutely avoid in patients with active bleeding or history of significant hematuria episodes.[33]
- Berberine and high-dose berberine-containing supplements (goldenseal, Oregon grape): Urothelial irritant at high doses. May worsen dysuria and urgency in patients with active bladder mucosal disease. Also significant CYP3A4/CYP2D6 inhibitor — alters metabolism of opioids and other hospice medications.
- Betaine/TMG at high doses: Theoretical urothelial irritation at supraphysiologic doses. Insufficient safety data in active bladder cancer. Avoid in patients with symptomatic bladder disease.
Timeline Guide
A guide, not a prediction. Every patient's trajectory is shaped by histology, molecular profile, treatment response, urinary diversion type, and comorbidities.
Bladder cancer trajectory varies enormously based on whether disease is non-muscle-invasive (years of recurrence and surveillance) or muscle-invasive/metastatic (months). Patients with prior cystectomy and urinary diversion carry a fundamentally different symptom profile than those with intact bladders. Renal function trajectory — driven by ureteral obstruction — is often the most reliable predictor of timeline. Immunotherapy responders can have dramatically different courses than non-responders.[2]
YRS–
MOS
MOS
NMIBC Surveillance Phase
- Recurrent TURBT procedures every 3–12 months depending on risk stratification; BCG maintenance therapy cycles; annual upper tract imaging
- Patients are functionally well but living with chronic disease and recurrence anxiety — every cystoscopy is a source of dread
- Lifestyle modifications: smoking cessation (reduces recurrence risk), occupational exposure avoidance, hydration
- Palliative care integration is rarely offered at this stage but advance care planning conversations are appropriate — especially for high-risk NMIBC patients who may progress to muscle-invasive disease[8]
MOS–
1 YR
1 YR
MIBC Post-Cystectomy / Metastatic on First-Line Therapy
- Urinary diversion adjustment is ongoing — learning to manage ileal conduit (stoma appliance care, skin protection, bag changes), neobladder (continence training, intermittent catheterization), or continent pouch (catheterization schedule)
- Systemic therapy toxicity: cisplatin-related nephrotoxicity, ototoxicity, neuropathy; gemcitabine-related myelosuppression; immunotherapy immune-related adverse events[19]
- Bone and lymph node metastases developing; performance status still adequate (ECOG 0–2) but fatigue and pain increasing
- This is the window for palliative care integration and it is almost always missed — palliative care referral should occur at diagnosis of metastatic disease, not at treatment failure[26]
WKS–
MOS
MOS
Hospice Transition / Preterminal
- Metastatic progression through platinum and immunotherapy — treatment options exhausted or performance status inadequate for further systemic therapy
- Hematuria increasing in frequency and severity; pelvic pain requiring regular opioid management; ureteral obstruction developing with rising creatinine[4]
- ECOG declining to 2–3; bed-bound for increasing portions of the day; weight loss accelerating; urinary diversion complications becoming more frequent (stoma problems, catheter issues, stomal hernia)
- Hospice enrollment most appropriate here — comfort kit preparation, family education on catheter/stoma management, goals-of-care finalization, ureteral stent exchange plan documented
DAYS–
WKS
WKS
Active Dying — Pre-Active Phase
- Hematuria may be continuous; ureteral stents possibly in place — know who manages them and when they need exchange; this is a clinical detail that cannot wait for a crisis
- Conversion to SQ medications as oral route fails — morphine or hydromorphone SQ, midazolam SQ, glycopyrrolate SQ
- Pelvic pain requiring around-the-clock opioids with gabapentin and dexamethasone adjuncts; neuropathic pain component often dominant at this stage
- Urinary output declining with progressive renal failure; fatigue and somnolence dominant; minimal oral intake[34]
- Family teaching priorities: what to do if catheter stops draining (clot retention protocol), signs of urosepsis (fever + confusion = call nurse immediately), what declining urine output means
HRS–
DAYS
DAYS
Final Hours
- Urinary output may cease entirely — anuria from renal failure or complete obstruction. This is a comfort decision: whether to manage (irrigation, catheter manipulation) or accept as part of the dying process
- Conversion to SQ route complete; continuous subcutaneous infusion (CSCI) if available; morphine + midazolam + glycopyrrolate as needed
- Cheyne-Stokes breathing; mottling of extremities; mandibular breathing; peripheral cyanosis
- Unresponsive or minimally responsive — auditory awareness may persist; family should be told to speak normally and assume the patient can hear
- Catheter or stoma remains in place for comfort — do not remove; management is passive at this point; family presence is the clinical priority[34]
Medications to Anticipate
Symptom-targeted pharmacology for bladder cancer. What to have in the comfort kit, what to titrate first, and what the evidence supports.
The dominant symptoms driving medication decisions in bladder cancer are pelvic pain (often neuropathic from sacral plexus invasion), hematuria management, nausea from both uremia and opioid use, and prevention of urosepsis. Pain management in this disease requires multimodal approaches — opioid escalation alone in the setting of neuropathic pelvic pain leads to clinical frustration for both patient and clinician.[35]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Morphine / Oxycodone | Opioid / Pelvic pain | Morphine 5–10 mg PO q4h ATC or Oxycodone 5 mg PO q4h | First-line for moderate-severe pelvic pain. Titrate aggressively — do not undertreat pelvic cancer pain. Pelvic pain may be severe and neuropathic in character. Convert to SQ morphine (1/3 of oral dose) when oral route fails.[35] Adjust for renal impairment — common in bladder cancer from obstruction. Hydromorphone preferred if GFR <30. |
| Gabapentin | Anticonvulsant / Neuropathic pelvic pain | 300 mg PO TID, titrate to 900 mg TID | Bladder and pelvic floor nerve involvement is common — sacral plexus invasion causes burning, shooting neuropathic pain. Pelvic radiation also causes neuropathic pain. Add gabapentin early — do not wait for opioid failure. Reduce dose in renal impairment.[35] |
| Dexamethasone | Corticosteroid / Anti-edema, appetite, pain adjunct | 4–8 mg PO/SQ daily (morning) | May temporarily relieve partial ureteral obstruction by reducing periureteral and peritumoral edema. Also improves appetite, energy, and overall symptom burden. Taper after 2 weeks if possible.[36] |
| Tamsulosin | Alpha-blocker / Ureteral stent pain, urinary spasm | 0.4 mg PO daily | Reduces ureteral smooth muscle spasm, facilitates stent tolerance, and reduces stent-related flank pain and dysuria. This is an underused comfort drug in bladder cancer patients with ureteral stents. Also reduces bladder outlet spasm.[37] Monitor for orthostatic hypotension — common in elderly, dehydrated patients. |
| Tranexamic Acid | Antifibrinolytic / Hematuria | 1 g PO TID or 1 g IV q8h | Oral antifibrinolytic — reduces bleeding in active hematuria. Can be highly effective. ⚠ CRITICAL: Stop if clots are forming in the bladder. These drugs prevent clot dissolution — in patients with clot retention, tranexamic acid worsens the problem by stabilizing clots that cannot be evacuated.[38] |
| Aminocaproic Acid | Antifibrinolytic / Hematuria | 5 g PO load, then 1 g PO q4h | Alternative antifibrinolytic to tranexamic acid. Same mechanism, same cautions. Available IV and PO. Same clot retention risk — do not use if clots are already present in catheter drainage.[38] |
| Haloperidol | Antipsychotic / Nausea | 0.5–1 mg PO/SQ q8h | Opioid-induced and uremia-related nausea — both common in bladder cancer. Haloperidol is first-line for central nausea in hospice. Low doses are usually sufficient.[34] |
| Ondansetron | 5-HT3 antagonist / Nausea adjunct | 4–8 mg PO/SQ q8h PRN | Nausea adjunct. ⚠ Caution: QTc prolongation — avoid in patients on other QTc-prolonging agents. Causes constipation — address proactively. |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg PO/SQ q4–6h PRN | Urinary symptoms generate profound anxiety — the constant awareness of bleeding, leaking, and loss of control. Address pharmacologically alongside psychosocial support.[34] |
| Midazolam | Benzodiazepine / Terminal agitation | 2.5–5 mg SQ PRN or 10–30 mg/24h CSCI | Terminal agitation and refractory symptom management. Have in comfort kit drawn and labeled. Essential for catastrophic hemorrhage protocol — sedation before distress. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h | Reduces terminal secretions without CNS effects. Preferred over hyoscine in conscious patients. Standard end-of-life medication — have in comfort kit. |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adaptedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for Bladder Cancer
Clot retention crisis: For patients with significant hematuria and catheter in place — clot retention is a urological emergency that causes severe suprapubic pain and complete urinary obstruction. The family must know the signs: catheter stops draining, patient develops severe lower abdominal pain and agitation, visible clots in tubing. Have a bladder irrigation protocol written and reviewed with the family at enrollment. Keep large syringes (60 mL catheter-tip) at bedside for manual irrigation.
Ureteral stent management: For patients with ureteral stents — stent exchange is a scheduled procedure (every 3–6 months typically). Know the exchange interval, know who manages it (urology vs. interventional radiology), and have the clinical plan written in the chart before the stent fails. A retained obstructed stent causes urosepsis, which is a painful and entirely preventable crisis.
Catastrophic hemorrhage kit: Dark towels, midazolam 5 mg SQ pre-drawn and labeled, morphine SQ pre-drawn. Family must know: cover the bleeding, administer midazolam, call the nurse. The goal is sedation before distress — not hemostasis.
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
1
Know the urinary anatomy before the visit
Ileal conduit, neobladder, continent pouch, bilateral nephrostomy tubes, ureteral stents — each creates a completely different clinical problem set. Do not walk into an HCC visit thinking about a bladder cancer patient's urinary system without knowing exactly what surgical alterations have been made. Write the diversion type on the front of the chart. An ileal conduit patient with hematuria is managed entirely differently from a neobladder patient with hematuria. A patient with bilateral nephrostomy tubes has a different obstruction risk profile than one with retrograde ureteral stents. This is the most important single piece of information in bladder cancer.[10]
2
Hematuria assessment — objectively, every visit
Hematuria in bladder cancer exists on a spectrum from mild pink urine to catastrophic hemorrhage. Assess severity objectively at every visit using urine color grading (clear, pink, rose, red, dark red with clots) and the presence or absence of clots. A patient with persistent gross hematuria and stable clots is clinically different from a patient with active arterial bleeding. Families often normalize what they've been watching gradually worsen — they need the clinician to name the change. Track urine color over time in the visit notes.[24]
3
Tranexamic acid is underused in hospice hematuria management
Oral tranexamic acid (1 g TID) is an antifibrinolytic that reduces bladder bleeding effectively and is available, inexpensive, and well-tolerated. Most hospice teams have never ordered it. The critical caveat: it must be stopped if clots are forming in the bladder, because these drugs prevent clot dissolution — making clot retention worse, not better. The clinical decision is binary: active bleeding without clots → use it; clots forming or present → stop it immediately. This nuance must be documented clearly in the care plan.[38]
4
Ureteral stent management is a time-sensitive clinical responsibility
Most ureteral stents require exchange every 3–6 months. A stent that becomes encrusted or obstructed causes hydronephrosis, urosepsis, and severe flank pain. Know the stent exchange date, know who manages it (urology vs. interventional radiology), and have a clinical plan written in the chart before the stent fails. This is not a theoretical risk — it is a predictable event with a known timeline. Add the stent exchange date to the care plan with the same urgency you would add a medication renewal date. A forgotten stent exchange is an entirely preventable crisis.[11]
5
Pelvic pain is neuropathic — treat it multimodally
Pelvic pain in bladder cancer is often neuropathic from sacral plexus invasion, tumor infiltration of pelvic floor nerves, or post-radiation neuropathy. It responds better to a multimodal approach than opioids alone. Add gabapentin early (300 mg TID, titrate up), consider dexamethasone for periureteral edema (4–8 mg daily), use alpha-blockers (tamsulosin 0.4 mg daily) for stent-related pain and bladder spasm. Do not escalate opioids in isolation when the pain mechanism is neuropathic — the patient will become sedated and still hurt. Name the pain type, treat the mechanism.[35]
"I've lost count of how many bladder cancer patients I've walked in on where nobody on the team knew the diversion type. You'd ask 'what kind of urinary surgery did he have?' and the answer was 'I think he has a bag?' That is not good enough. Ileal conduit, neobladder, continent pouch, nephrostomy tubes — they are all different. Know it or look it up before you drive there."
— Waldo, NP
Psychosocial & Spiritual Care
Existential distress, depression screening, spiritual assessment, and the unique dignity crisis of bladder cancer at end of life.
Psychosocial and spiritual distress in bladder cancer has a unique dimension that sets it apart from other malignancies: the disease attacks the most intimate functions of the body. Loss of urinary control, visible stoma bags, catheter tubes, and hematuria are profoundly humiliating for many patients. Depression affects 20–30% of hospice patients with bladder cancer and is systematically underdiagnosed because clinicians — and patients — often attribute emotional suffering to the "expected" distress of the physical symptoms.[39]
Your job is not to provide the answers. Your job is to open the door to conversations that most people in this patient's life have been avoiding — conversations about shame, about the body they no longer recognize, about the private functions they can no longer control.
Bladder Cancer-Specific Psychosocial Themes
Urinary Dignity and Shame
Loss of urinary control, visible stoma bags, catheter tubes, and blood in the urine are profoundly humiliating for many patients. Bladder cancer attacks bodily functions that adults learn to control in early childhood — losing that control feels like regression to a state of helplessness. Address body image and dignity explicitly. Create space for patients to name this shame without minimizing it. Do not say "it's nothing to be embarrassed about" — instead say "this is hard, and it makes sense that it's hard."[40]
Stoma Adjustment and Grief
Patients with ileal conduits or continent pouches have undergone permanent alteration of their body. The adjustment to stoma life is a grief process — grief for the body as it was, for spontaneity lost, for the constant visible reminder of disease. Many patients on hospice have never fully completed that adjustment, especially if cystectomy was recent. Chaplain and social work involvement is essential. Ask: "How has living with the stoma been for you — not just physically, but emotionally?"[40]
Tobacco Guilt
Many bladder cancer patients smoked and know it contributed to their disease. They carry guilt silently — often compounded by family members who said "I told you to quit." Address it directly at enrollment: "Smoking is an addiction, not a moral failure. You did not choose cancer." This simple statement, said with clinical authority, can release years of accumulated shame. Do not wait for the patient to bring it up — they rarely will.[13]
Occupational Exposure Grief
Patients who developed bladder cancer from workplace chemical exposures often carry anger about their employers and the system that exposed them without adequate protection. This is legitimate grief and legitimate anger — do not pathologize it. Validate it: "You were exposed to chemicals that caused this disease while doing your job. It is understandable that you are angry." Social work may explore potential VA benefits, workers' compensation claims, or legal resources if applicable.
Sexual Function and Intimacy
Radical cystectomy in men causes erectile dysfunction (nerve damage during prostatectomy component). In women, removal of the anterior vaginal wall causes significant sexual anatomy changes, vaginal shortening, and dyspareunia. These losses are rarely addressed in hospice — clinicians are uncomfortable asking, patients are uncomfortable volunteering. Name them explicitly and normalize the grief: "Many patients who have had this surgery experience changes in sexual function and intimacy. This is a real loss. Would you like to talk about it?"[41]
Fear of Dying Without Dignity
Bladder cancer patients frequently express fear of dying while bleeding, smelling of urine, or losing bowel and bladder control completely. Address each fear clinically: explain what medications will prevent suffering (midazolam for hemorrhage distress, opioids for pain), explain what death actually looks like at the end of this disease (usually quiet, with declining consciousness and minimal distress if symptoms are managed), and document the conversation. Say: "I know what you're afraid of. Let me tell you what we will do to prevent that."[34]
Psychological Distress Screening
Depression — Screen Every Patient
Grade BSingle-question screen: "Are you depressed?" has 100% sensitivity in terminally ill populations when phrased directly.[42]
- PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants full PHQ-9
- Mirtazapine 7.5 mg QHS: First-line in hospice — addresses depression, insomnia, and anorexia simultaneously
- Distinguish depression from appropriate sadness — both deserve attention; only one warrants pharmacotherapy
Anxiety & Existential Distress
Grade B- Distinguish anxiety subtypes: Situational (catheter change, stoma leak), generalized, existential, death anxiety — each responds differently
- Lorazepam 0.5 mg PRN for acute anxiety episodes — bladder cancer patients have high baseline anxiety from urinary symptom unpredictability
- Dignity therapy: Structured life narrative intervention — particularly relevant in bladder cancer where dignity is the central psychosocial theme[43]
- Refer to social work and chaplain at enrollment — not at crisis
Spiritual Assessment
Use the FICA framework: Faith/beliefs, Importance, Community, Address. Ask: "What gives you strength during this time?" This opens spiritual conversation without assuming any tradition. For bladder cancer patients specifically, explore meaning-making around bodily suffering: "Some people find that physical suffering like this raises spiritual questions. Has that been true for you?"[42]
Clinical Pearl
"Bladder cancer patients carry their disease in the most private part of their body. Every symptom — the blood in the toilet, the bag on their side, the catheter between their legs — is a visible reminder of what the cancer has taken. Your clinical detachment is not neutrality. Name the dignity dimension explicitly. Ask directly: 'This disease affects very private parts of your life — how are you doing with that?'"
Suicidal Ideation & Hastened Death Requests
Passive wish for death ("I'm ready to go") is common and often existentially appropriate in end-stage bladder cancer — it is not the same as active suicidal ideation. Assessment requires careful distinction: passive wish for death (common, often appropriate), active suicidal ideation with plan (requires immediate psychiatric engagement), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol). In bladder cancer, loss of bodily dignity is a specific risk factor for suicidal ideation — do not avoid the question because the symptoms are uncomfortable to discuss.[42]
"I had a bladder cancer patient — retired pipe fitter, tough as nails — who wouldn't look at me for the first three visits. Wouldn't make eye contact. It wasn't anger. It was shame. When I finally said, 'I know this disease has taken away some very private things from you — how are you doing with that?' he broke down. He had been carrying it completely alone. Nobody had asked. Not his wife, not his doctor, not his kids. Just ask. That's all it takes sometimes."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
If you are reading this, someone you love has bladder cancer that has progressed beyond the point where treatment can cure the disease. What you are doing — being here, learning, staying present through difficult and sometimes frightening symptoms — is not ordinary. Bladder cancer at end of life can involve blood in the urine, tubes and bags that need to be managed, and pain that requires strong medication. All of these can be managed. Your care team is here to help you understand what is happening, what you can do, and when to call for help.
What You May See
- Blood in the urine or around the catheter: This can range from light pink to bright red. Tell the nurse the color and whether you can see any clots — small dark pieces in the urine or tubing. Blood in the urine is common in this disease and does not always mean an emergency, but changes should be reported.
- The catheter or bag stops draining: If the catheter bag stops collecting urine or you notice the tubing is blocked with dark material, this may be a blood clot blocking the flow. This causes pain and needs attention — call the nurse immediately. Do not try to fix it yourself.
- A bag attached to the side or abdomen (urostomy): If your loved one had their bladder removed, urine now drains through a small opening (stoma) into an external bag. Your nurse will teach you how to empty and manage it. This is not painful for the patient.
- Severe lower abdominal or pelvic pain: This is manageable with medication. Do not wait to report uncontrolled pain — the team can adjust medications to keep your loved one comfortable. Pain should be assessed at every nurse visit.
- Fever with chills and confusion: This may indicate a urinary tract infection or sepsis — it is a medical emergency in patients with bladder cancer, especially those with urinary tubes or stents. Call the nurse immediately.
- Extreme fatigue and loss of appetite: These are expected as the disease progresses. Small offerings of favorite foods are enough. Rest is appropriate. Do not push food or fluids beyond what the patient wants.
How You Can Help
- Empty the urostomy or catheter bag regularly: Your nurse will teach you the technique. Overfilling causes discomfort and leakage. This is a practical skill that makes a real difference in your loved one's comfort.
- Keep the area around the catheter or stoma clean and dry: Call the nurse if you see redness, new discharge, or a smell that is different from what you've been told to expect. These can be signs of infection or skin breakdown.
- Report any change in urine color immediately: Especially if it gets darker red, if clots appear, or if the amount of urine decreases noticeably. These changes help the nurse make medication and care decisions.
- Do not push fluids beyond comfort: Forcing fluid intake in the setting of kidney problems or urinary obstruction can cause harm. Ask the nurse first. Offer small sips of preferred beverages and follow the patient's lead.
- Protect their dignity: Manage all catheter and stoma care as privately as possible. Ask their permission before exposing the area. Close doors. Their comfort with being seen matters — even when they cannot express it verbally.
- Take care of yourself: The caregiving you are doing requires skills that most healthcare professionals train for years to learn. You are learning them in days. Accept help when it is offered. Use respite care. Call the hospice team when you need support — not just when the patient does.
📞 Call the nurse immediately if you see:
Catheter or stoma tube stops draining completely and patient has severe pain or abdominal distension — do not wait. Bright red bleeding that does not slow down or fills the tubing with clots rapidly. Fever above 101°F with confusion, shaking chills, or rapid heart rate (possible urosepsis — this is a medical emergency). Inability to wake the patient or sudden change in responsiveness. Severe pain that is not controlled by the medications you have been given — the dose can be adjusted, but only if we know it is not working.
🙏 The things you are doing for this person — learning to empty the bag, managing the catheter, staying present when the symptoms are frightening — are not ordinary acts of caregiving. They are extraordinary acts of love. Most people could not do what you are doing. The evidence is clear: patients who have someone present with them experience less suffering — not just emotionally, but physically. You are part of the clinical team whether you know it or not. What you are doing matters.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Know the urinary anatomy before you walk in. Ileal conduit, neobladder, bilateral nephrostomy, ureteral stents — each one is a different clinical landscape. Not knowing which one your patient has is like not knowing which cancer they have. I've seen nurses arrive at the home, see a bag on the abdomen, and assume it's a colostomy. It's not. An ileal conduit drains urine. A neobladder means the patient has a surgically constructed bladder from bowel and voids through the urethra — or tries to. Continent pouches require catheterization through an abdominal channel. Write the anatomy on the front page of the chart. Read the surgical note. Ask the patient. Just know it before you start managing symptoms.
- 02Hematuria is a spectrum. Pink urine is different from clots filling a catheter bag. You need to assess it objectively at every visit — not just ask "any blood?" and move on. Look at the urine yourself. Grade the color. Note whether there are clots. Ask the family what the worst episode looked like this week. Families normalize what they've been watching get gradually worse because nobody has told them what matters. A catheter bag full of dark red clots is not the same as tea-colored urine. One needs emergent attention; the other needs monitoring. Teach the family the difference and write a clear protocol in the chart for what to do at each level.
- 03Tranexamic acid is underused. Oral antifibrinolytic for hematuria. One gram, three times a day. It works, it is inexpensive, and most hospice teams have never ordered it for bladder bleeding. Learn it. Use it. The critical caveat — and this is the part you absolutely must get right — is that you stop it if clots are forming. Tranexamic acid prevents clots from dissolving. If your patient already has clots in the bladder, this drug makes it worse by stabilizing those clots so they cannot be washed out. Active bleeding without clots? Use it. Clots present or forming? Stop it immediately. Write that decision tree in the care plan.
- 04Ureteral stent exchange dates are a clinical time bomb. Most stents need to come out or be exchanged every 3–6 months. When they encrust or block, the patient develops hydronephrosis, then sepsis, then severe pain — and the family is calling the on-call line at 2 AM wondering why he's suddenly febrile and delirious. This is entirely preventable. At enrollment, find out: are stents in place? When were they placed? When are they due for exchange? Who manages them — urology or interventional radiology? Write the exchange date in the care plan with the provider's name and phone number. Set a reminder two weeks before the date. A missed stent exchange is a clinical failure, not bad luck.
- 05Pelvic pain in bladder cancer is neuropathic. Add gabapentin early. Add dexamethasone for periureteral edema. Use alpha-blockers like tamsulosin for stent-related pain and bladder spasm. I have watched too many patients get their morphine doubled, then tripled, then quadrupled — and they're still in pain but now they can't stay awake. That's not treating pain; that's sedating someone who still hurts. Neuropathic pelvic pain — burning, shooting, electric — does not respond to opioid escalation alone. It responds to gabapentin, to nerve-modulating agents, to reducing the inflammation around the ureters and the tumor. Treat the mechanism, not just the complaint.
- 06Hemostatic radiation is a comfort intervention, not cancer treatment. A 5-fraction course of palliative radiation that stops catastrophic hematuria is comfort care. It is not "continuing treatment." It is not "fighting the cancer." It is preventing a man from bleeding into his catheter bag until he needs transfusions or until the family watches something no family should watch. Have this conversation with the patient's radiation oncologist before the bleeding crisis, not during it. Many radiation oncologists will see hospice patients for hemostatic radiation — you just have to ask. Do it early. Do it proactively. Write the referral pathway in the care plan.
- 07Dignity is the clinical theme. Bladder cancer takes the most private functions of the body. Ask directly about shame. Ask about the stoma. Ask about sexual function that has been lost. Ask about the fear of dying smelling of urine. Do not skip these conversations because they are uncomfortable — the patient has been carrying them alone since diagnosis and nobody has asked. I ask every bladder cancer patient: "This disease affects very private parts of your life. How are you doing with that?" It is the most important question I ask in the entire visit, and it takes ten seconds. The answer changes everything about how I frame the rest of the care plan.
- 08Tobacco guilt is almost universal. Address it at enrollment. Not at the third visit. Not when they bring it up. At enrollment. Every bladder cancer patient who smoked knows that smoking caused their disease. Many have family members who said "I told you so" — sometimes out loud, sometimes just with their eyes. Addiction is a disease. Nicotine is as addictive as heroin. They did not choose cancer. Say it out loud. Say it like you mean it. Say it in front of the family. "Smoking is an addiction. You did not choose this. And the only thing that matters now is making you comfortable." I have watched patients' shoulders drop six inches after hearing those words. They've been waiting for someone with clinical authority to say it for years.
- 09Urosepsis is preventable with vigilance. Fever plus altered mental status in a patient with urinary diversion, ureteral stents, or an indwelling catheter is sepsis until proven otherwise. Do not wait for the blood cultures. Do not wait for the white count. If a bladder cancer patient with any kind of urinary hardware spikes a fever and gets confused, call the physician and start the sepsis protocol. Have the urosepsis plan written in the care plan — which antibiotic to call for, whether to initiate at home or send to the ED, what the family should do while waiting. Review it with the family before it happens, not during the 2 AM phone call. Preparation is the treatment for urosepsis. Not antibiotics. Preparation.
- 10Caregiver burden in bladder cancer is underestimated by everyone, including us. Managing a stoma, a catheter, hematuria, and pelvic pain from home requires clinical-level skills from a family member who has had no training. They are learning to empty bags of bloody urine, to troubleshoot blocked catheters, to manage irrigation, to clean a stoma — all while watching someone they love die. Assess the caregiver separately at every single visit. Not "how are you doing?" in passing while you pack up your bag. Sit down. Ask them directly. Connect them to ostomy nursing support if available. Prescribe respite care before they ask for it. The caregiver who crashes does not send up a flare — they just stop answering the phone. By then it is too late. Check on them like they are your patient, because functionally, they are.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49.
2
Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA. 2020;324(19):1980-1991.
3
Dobruch J, Daneshmand S, Fisch M, et al. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol. 2016;69(2):300-310.
4
Ghosh A, Somashekhar SP, Gulia S. Symptom Management in Advanced Bladder Cancer: Challenges and Approaches. Indian J Palliat Care. 2019;25(3):448-454.
5
Burger M, Catto JW, Dalbagni G, et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer. Eur Urol. 2013;63(2):234-241.
6
Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (2024 Update). Eur Urol. 2024;85(3):290-314.
7
Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021;79(1):82-104.
8
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016;196(4):1021-1029.
9
Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 1999;12(1):97-111.
10
Lee RK, Abol-Enein H, Artibani W, et al. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int. 2014;113(1):11-23.
11
Kouba E, Wallen EM, Pruthi RS. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol. 2008;180(2):444-450.
12
Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129.
13
Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737-745.
14
Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol. 2018;74(6):784-795.
15
Wallis CJ, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016;352:i851.
16
Hale NE, Murphy AB, Ellison CK, et al. Racial disparities in bladder cancer outcomes and access to care. Urol Oncol. 2022;40(4):163.e1-163.e8.
17
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis. Eur Urol. 2005;48(2):202-205.
18
Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer. Eur Urol. 2017;71(2):295-299.
19
von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068-3077.
20
De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191-199.
21
Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-045). N Engl J Med. 2017;376(11):1015-1026.
22
Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer (EV-302). N Engl J Med. 2024;390(10):875-888.
23
Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma (THOR). N Engl J Med. 2023;389(21):1961-1971.
24
Ghahestani SM, Shakhssalim N. Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review. Urol J. 2009;6(3):149-156.
25
Duchesne GM, Bolger JJ, Griffiths GO, et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000;47(2):379-388.
26
Catto JWF, Downing A, Mason S, et al. Quality of Death in Bladder Cancer: A National Retrospective Cohort Study. Eur Urol. 2021;80(3):370-378.
27
Chiu HY, Hsieh YJ, Tsai PS. Systematic review and meta-analysis of acupuncture to reduce cancer-related pain. Eur J Cancer Care. 2017;26(2):e12457.
28
Haller H, Winkler MM, Klose P, et al. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. Acta Oncol. 2017;56(12):1665-1673.
29
Centemero A, Rigatti L, Giraudo D, et al. Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: a randomised controlled study. Eur Urol. 2010;57(6):1039-1043.
30
Marx W, Ried K, McCarthy AL, et al. Ginger — Mechanism of action in chemotherapy-induced nausea and vomiting: A review. Crit Rev Food Sci Nutr. 2017;57(1):141-146.
31
Luo KW, Lung WY, Chun-Xie, Luo XL, Huang WR. EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway. Oncotarget. 2018;9(15):12261-12272.
32
Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ. 2003;327(7429):1454.
33
Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(7):695-712.
34
Cherny NI, Fallon M, Kaasa S, Portenoy RK, Currow DC. Oxford Textbook of Palliative Medicine, 6th Edition. Oxford University Press. 2021.
35
Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv166-iv191.
36
Paulsen Ø, Klepstad P, Rosland JH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014;32(29):3221-3228.
37
Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ. Meta-analysis showing best management for ureteral stent symptoms. J Endourol. 2011;25(11):1715-1718.
38
Tran A, Lee G. Tranexamic acid for the treatment of hematuria: a systematic review. Urology. 2022;160:32-39.
39
Mohamed NE, Herrera PC, Hudson S, et al. Muscle invasive bladder cancer: examining survivor burden and unmet needs. J Urol. 2014;191(1):48-53.
40
Cerruto MA, D'Elia C, Siracusano S, et al. Systematic review and meta-analysis of non RCT's on health related quality of life after radical cystectomy using validated questionnaires: Better results with orthotopic neobladder versus ileal conduit. Eur J Surg Oncol. 2016;42(3):343-360.
41
Modh RA, Mulhall JP, Gilbert SM. Sexual dysfunction after cystectomy and urinary diversion. Nat Rev Urol. 2014;11(8):445-453.
42
Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA. 2000;284(22):2907-2911.
43
Chochinov HM, Kristjanson LJ, Breitbart W, et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol. 2011;12(8):753-762.
44
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy (IMvigor210). Lancet. 2016;387(10031):1909-1920.
45
Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052). Lancet Oncol. 2017;18(11):1483-1492.
46
Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-675.
47
Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432-2438.
48
Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044-3050.
49
Kulkarni GS, Hermanns T, Wei Y, et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017;35(20):2299-2305.
50
Temel JS, Greer JA, Muzikansky A, et al. Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2010;363(8):733-742.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.